RSPR-007 Mannitol Challenge Trial

• Status: Completed
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a double-blind, randomised, placebo-controlled, cross-over, Phase 2 trial evaluating two doses (a low and a high) of CRD007 for the treatment of asthmatic trial subjects with a positive asthma test (mannitol challenge) prior to enrolment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: RSPR Pharma AB
• Treatments: Mannitol; Pemirolast

Criteria

Inclusion Criteria:

• Written informed consent

• Age ≥18 and <50 years

• Diagnosis of asthma

Exclusion Criteria:

• Clinical significant comorbidities

• Lower respiratory tract infection <6 weeks prior to Visit 1

• Others, as specified in the protocol